Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have received a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $11.36.

Several brokerages have issued reports on VOR. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a report on Monday, December 9th. JMP Securities restated a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Finally, Robert W. Baird lowered their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $1.56 on Friday. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14. The stock has a market cap of $106.79 million, a price-to-earnings ratio of -0.94 and a beta of -0.51. The firm’s 50-day moving average is $0.99 and its 200-day moving average is $0.91.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). Sell-side analysts predict that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Institutional Trading of Vor Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of VOR. Hsbc Holdings PLC grew its holdings in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Vor Biopharma during the second quarter worth about $53,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vor Biopharma during the second quarter worth about $63,000. Rosalind Advisors Inc. acquired a new stake in Vor Biopharma during the third quarter worth about $54,000. Finally, Acadian Asset Management LLC increased its holdings in Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after buying an additional 27,597 shares during the period. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.